Pituitary carcinoma

a review of the literature.

Brian T. Ragel, William T. Couldwell

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Pituitary carcinomas, defined as distant metastases of a pituitary neoplasm, are rare; fewer than 140 reports exist in the English literature. The initial presenting pituitary tumor is usually a secreting, invasive macroadenoma, with adrenocorticotropic hormone (ACTH)--and prolactin (PRL)--secreting tumors being the most common. The latency period between the diagnosis of a pituitary tumor and the diagnosis of a pituitary carcinoma is 9.5 years for ACTH-producing lesions and 4.7 years for PRL-secreting tumors. Survival after documentation of metastatic disease is poor; 66% of patients die within 1 year. Treatment options include additional surgery, radiotherapy, and chemotherapy, all of which are associated with poor results. Future studies will focus on identifying those invasive pituitary tumors most likely to metastasize and treating them aggressively before they progress to pituitary carcinomas.

Original languageEnglish (US)
JournalNeurosurgical Focus
Volume16
Issue number4
StatePublished - 2004
Externally publishedYes

Fingerprint

Pituitary Neoplasms
Prolactin
Adrenocorticotropic Hormone
Literature
Documentation
Neoplasms
Radiotherapy
Neoplasm Metastasis
Drug Therapy
Survival

Cite this

Ragel, B. T., & Couldwell, W. T. (2004). Pituitary carcinoma: a review of the literature. Neurosurgical Focus, 16(4).

Pituitary carcinoma : a review of the literature. / Ragel, Brian T.; Couldwell, William T.

In: Neurosurgical Focus, Vol. 16, No. 4, 2004.

Research output: Contribution to journalArticle

Ragel, BT & Couldwell, WT 2004, 'Pituitary carcinoma: a review of the literature.', Neurosurgical Focus, vol. 16, no. 4.
Ragel, Brian T. ; Couldwell, William T. / Pituitary carcinoma : a review of the literature. In: Neurosurgical Focus. 2004 ; Vol. 16, No. 4.
@article{c4f6769c16bf42cd93f6f9798a1ea8b1,
title = "Pituitary carcinoma: a review of the literature.",
abstract = "Pituitary carcinomas, defined as distant metastases of a pituitary neoplasm, are rare; fewer than 140 reports exist in the English literature. The initial presenting pituitary tumor is usually a secreting, invasive macroadenoma, with adrenocorticotropic hormone (ACTH)--and prolactin (PRL)--secreting tumors being the most common. The latency period between the diagnosis of a pituitary tumor and the diagnosis of a pituitary carcinoma is 9.5 years for ACTH-producing lesions and 4.7 years for PRL-secreting tumors. Survival after documentation of metastatic disease is poor; 66{\%} of patients die within 1 year. Treatment options include additional surgery, radiotherapy, and chemotherapy, all of which are associated with poor results. Future studies will focus on identifying those invasive pituitary tumors most likely to metastasize and treating them aggressively before they progress to pituitary carcinomas.",
author = "Ragel, {Brian T.} and Couldwell, {William T.}",
year = "2004",
language = "English (US)",
volume = "16",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "4",

}

TY - JOUR

T1 - Pituitary carcinoma

T2 - a review of the literature.

AU - Ragel, Brian T.

AU - Couldwell, William T.

PY - 2004

Y1 - 2004

N2 - Pituitary carcinomas, defined as distant metastases of a pituitary neoplasm, are rare; fewer than 140 reports exist in the English literature. The initial presenting pituitary tumor is usually a secreting, invasive macroadenoma, with adrenocorticotropic hormone (ACTH)--and prolactin (PRL)--secreting tumors being the most common. The latency period between the diagnosis of a pituitary tumor and the diagnosis of a pituitary carcinoma is 9.5 years for ACTH-producing lesions and 4.7 years for PRL-secreting tumors. Survival after documentation of metastatic disease is poor; 66% of patients die within 1 year. Treatment options include additional surgery, radiotherapy, and chemotherapy, all of which are associated with poor results. Future studies will focus on identifying those invasive pituitary tumors most likely to metastasize and treating them aggressively before they progress to pituitary carcinomas.

AB - Pituitary carcinomas, defined as distant metastases of a pituitary neoplasm, are rare; fewer than 140 reports exist in the English literature. The initial presenting pituitary tumor is usually a secreting, invasive macroadenoma, with adrenocorticotropic hormone (ACTH)--and prolactin (PRL)--secreting tumors being the most common. The latency period between the diagnosis of a pituitary tumor and the diagnosis of a pituitary carcinoma is 9.5 years for ACTH-producing lesions and 4.7 years for PRL-secreting tumors. Survival after documentation of metastatic disease is poor; 66% of patients die within 1 year. Treatment options include additional surgery, radiotherapy, and chemotherapy, all of which are associated with poor results. Future studies will focus on identifying those invasive pituitary tumors most likely to metastasize and treating them aggressively before they progress to pituitary carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=4644336258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644336258&partnerID=8YFLogxK

M3 - Article

VL - 16

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 4

ER -